NEWS RELEASE: DP Clinical-Supported Study Results in FDA Approval of ADMA Biologics’ ASCENIV™

ROCKVILLE, MD – September 18, 2019 – DP Clinical, Inc., a Contract Research Organization (CRO) specializing in infectious disease, neuroscience, oncology, and ophthalmology Phase I-III clinical programs; congratulates ADMA Biologics’ on the approval of ASCENIV™ (immune globulin intravenous, human – slra 10% liquid). DP Clinical provided a full complement of CRO services for ADMA Biologics program (formerly referred to as RI-002) indicated for the treatment of Primary Humoral Immunodeficiency Disease (PIDD) in adults and adolescents. Click here to read more.

2019-09-18T16:30:22+00:00